The key players in the digital PCR and real-time PCR (qPCR) market focused on various strategies such as product launches and approvals; partnerships, collaborations and agreements; mergers and acquisitions; and expansions to enhance their presence in the global market. Product approvals, launches, and enhancements were the key strategies adopted by a majority of industry players to achieve growth in the dPCR and qPCR market. Several prominent dPCR and qPCR product manufacturers such as Thermo Fisher Scientific Inc., Bio-Rad Laboratories, F. Hoffman-la Roche Ltd., QIAGEN N.V., and Takara Bio, Inc. are focused on the development and commercialization of innovative dPCR and qPCR instruments and qPCR reagents to keep pace with the ongoing industry trends and to maintain their revenue base.
Thermo Fisher Scientific Inc. (U.S.) held the leading position in the global dPCR and qPCR market in 2016. The company possesses a robust qPCR and dPCR product portfolio that includes key brands such as the QuantStudio qPCR system, Veriti, and TaqMan reagents. The company has a strong geographic presence in more than 100 countries across the globe, with key markets in the U.S., China, Germany, and the U.K. The company mainly focuses on developing technologically advanced qPCR and dPCR products as well as reagents that are used for medical diagnostic research by clinical, pharmaceutical, industrial, and food safety laboratories. In line with this strategy, the company launched several qPCR and dPCR systems, reagents, and kits in the last three years, including QuantStudio 3 and 5, Real-time PCR system, TaqMan Assays, and qPCR MasterMixes. These product launches helped to expand the company’s existing qPCR/dPCR product portfolio and increase its revenue base in the global market. The company also adopted inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen its position in the market. In accordance with this, in January 2016, Thermo Fisher Scientific acquired Affymetrix Inc. (a U.S.-based company and leader in providing cellular and genetic analysis products) to expand the cellular and genetic analysis product market across North America.
Know the insights, Download Brochure:
https://www.marketsandmarkets.com/pdfdownload.asp?id=174151204
Bio-Rad Laboratories Inc. (U.S.) held the second position in the global dPCR and qPCR market in 2016. The company possesses a well-established brand position across the life sciences and clinical diagnostics market, which includes a broad range of technologically advanced products (including qPCR and dPCR devices). To strengthen its current position and gain a larger market share, Bio-Rad Laboratories aggressively focuses on strengthening its R&D and product manufacturing capabilities for the qPCR and dPCR market. During 2014 to 2017, the company launched several innovative qPCR and dPCR devices, including the QX200 Droplet Digital PCR (ddPCR) system, PrimePCR Droplet Digital PCR (ddPCR) Assays, and CFX Automation System II (a robotic plate-handling system), among others. Moreover, the company adopted merger and acquisition strategy to strengthen its market position and expand its product offerings. In line with this strategy, the company acquired RainDance Technologies (U.S.) in February 2017. Furthermore, the company also focuses on expanding its product distribution networks across major markets through agreements, expansions, and partnerships with key qPCR and dPCR market stakeholders.
As of 2016, some of the other players competing in this market are F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (U.S.), Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Fluidigm Corporation (U.S.), Danaher Corporation (U.S.), and Abbott Laboratories (U.S.), among others.
